Our Verdict
Prime Peptides (Prime Vitality, Inc.) received an FDA warning letter on December 10, 2024 — part of a four-vendor enforcement wave that also targeted Swiss Chems, Xcel Peptides, and Summit Research. The FDA cited the company for selling semaglutide, tirzepatide, and retatrutide as unapproved drugs with evidence of intended human use, in violation of FDCA sections 505(a) and 301(d). The company was given 15 days to respond with corrective procedures. On the chemistry side, a BPC-157 batch (lot 5132025BP, July 2025) tested at 82.39% purity — a confirmed quality failure on the most commonly purchased peptide they carry. Other tested products run clean. No physical address, no ownership disclosure. The FDA action, the BPC-157 failure, and the missing identity transparency make this a vendor we cannot recommend.
Latest Lab Results
| Vendor Score | 46/100 (Watchlist) |
| Latest Tested Batch(Jul 2025) | GHK-Cu — 99.8% Purity |
| Batch Grade | A |
| Tested By | Lab E |
Shipping & Payment
Community Sentiment
Several users have shared positive experiences with Prime Peptides, particularly praising their pricing. One user noted they spent $95 for enough Semaglutide peptide for 7 doses, highlighting the affordability of their products. Additionally, another post mentioned that the ordering process is excellent and includes discounts for subscription options.
Score Breakdown
Peptide Inventory (17)
| Peptide | Price | Status |
|---|---|---|
| AOD 9604 | $60.00 | In Stock |
| BPC-157 | $55.00 | In Stock |
| CJC & Ipa | $80.00 | In Stock |
| GHK-Cu | $60.00 | In Stock |
| Ipamorelin | $60.00 | In Stock |
| Melanotan I | $45.00 | In Stock |
| Melanotan II | $40.00 | In Stock |
| MOTS-c | $60.00 | In Stock |
| NAD+ | $135.00 | In Stock |
| Retatrutide | $110.00 | In Stock |
| Selank | Semax | $90.00 | In Stock |
| Semaglutide | $70.00 | In Stock |
| Semax | $45.00 | In Stock |
| Sermorelin | $70.00 | In Stock |
| TB-500 (TB4) | $65.00 | In Stock |
| Tesamorelin | $80.00 | In Stock |
| Tirzepatide | $100.00 | In Stock |